コリンエステラーゼ阻害薬
- 関
- acetylcholinesterase inhibitor、anticholinesterase、anticholinesterase agent
WordNet
- limit, block, or decrease the action or function of; "inhibit the action of the enzyme"; "inhibit the rate of a chemical reaction"
- control and refrain from showing; of emotions, desires, impulses, or behavior (同)bottle up, suppress
- limit the range or extent of; "Contact between the young was inhibited by strict social customs"
- a substance that retards or stops an activity
- an enzyme that hydrolyses acetylcholine (into choline and acetic acid)
PrepTutorEJDIC
- 〈感情・欲望・行動・作用など〉‘を'抑制する / (…しないように)〈人〉‘を'抑制する,妨げる《+『名』+『from』+『名』(do『ing』)》
- 抑制する人(物) / 化学反応抑制剤
Wikipedia preview
出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2013/06/30 12:48:59」(JST)
[Wiki en表示]
Not to be confused with ACE inhibitor.
Acetylcholinesterase inhibition
An acetylcholinesterase inhibitor (often abbreviated AChEI) or anti-cholinesterase is a chemical that inhibits the acetylcholinesterase enzyme from breaking down acetylcholine, thereby increasing both the level and duration of action of the neurotransmitter acetylcholine. Reversible, quasi-irreversible (or pseudirreversible in some sources) and irreversible inhibitors exist.[1]
Contents
- 1 Uses
- 2 Adverse effects
- 3 Examples
- 3.1 Reversible inhibitor
- 3.2 Quasi-irreversible inhibitor
- 3.3 Natural Compounds
- 4 Effects
- 5 Titration phase
- 6 See also
- 7 References
- 8 External links
|
Uses[edit]
Acetylcholinesterase inhibitors:[2]
- Occur naturally as venoms and poisons
- Are used as weapons in the form of nerve agents
- Are used as insecticides
- Are used medicinally:
- To treat myasthenia gravis. In myasthenia gravis, they are used to increase neuromuscular transmission.
- To treat glaucoma
- To treat Alzheimer's disease
- To treat Lewy Body Dementia
- To treat Postural Tachycardia Syndrome
- As an antidote to anticholinergic poisoning
- To reverse the effect of non-depolarising muscle relaxants
- To treat Apathy
Adverse effects[edit]
Potential side effects of acetylcholinesterase inhibitors[3][4] |
mild – usually goes away |
potentially serious |
- Diarrhea
- Headache
- Insomnia
- Nausea
- Vomiting
|
- Abdominal pain
- Lack of appetite
- Yellowed skin
- Dizziness
- Slow heartbeat
- Sudden or substantial weight loss
- Weakness
|
Examples[edit]
Reversible inhibitor[edit]
Compounds which function as reversible competitive or noncompetitive inhibitors of cholinesterase are those most likely to have therapeutic uses. These include:
- Some organophosphates not listed under "Irreversible" below
- Delta9-tetrahydrocannabinol (THC) [5]
- Carbamates
- Physostigmine
- Neostigmine
- Pyridostigmine
- Ambenonium
- Demarcarium
- Rivastigmine
- Phenanthrene derivatives
- Caffeine – noncompetitive (although an Adenosine receptor antagonist)[6]
- Piperidines
- Donepezil, also known as E2020
- Tacrine, also known as tetrahydroaminoacridine (THA')
- Edrophonium
- Huperzine A[7][8]
- Ladostigil
- Ungeremine[9]
- Lactucopicrin
Comparison table[edit]
Comparison of reversible acetylcholinesterase inhibitors
Inhibitor |
Duration |
Main site of action |
Clinical use |
Adverse effects |
Edrophonium |
short (10 min.)[10] |
neuromuscular junction[10] |
diagnosis of myasthenia gravis[10] |
|
Neostigmine |
medium (1–2 hrs.)[10] |
neuromuscular junction[10] |
- Reverse neuromuscular block (intravenously)[10]
- Treat myasthenia gravis (orally)[10]
|
visceral[10] |
Physostigmine |
medium (0.5-5 hrs.)[10] |
postganglionic parasympathetic[10] |
treat glaucoma (eye drops)[10] |
|
Pyridostigmine |
medium (2–3 hrs.)[10] |
neuromuscular junction[10] |
- Treat myasthenia gravis (orally)[10]
|
|
Dyflos |
long[10] |
postganglionic parasympathetic[10] |
historically to treat glaucoma (eye drops)[10] |
toxic[10] |
Ecothiopate (irreversible) |
long[10] |
postganglionic parasympathetic[10] |
treat glaucoma (eye drops)[10] |
systemic effects[10] |
Parathion (irreversible) |
long[10] |
none[10] |
toxic[10] |
Quasi-irreversible inhibitor[edit]
Compounds which function as quasi-irreversible inhibitors of cholinesterase are those most likely to have use as chemical weapons or pesticides. These include:
- Organophosphates
- Echothiophate
- Diisopropyl fluorophosphate
- Cadusafos
- Chlorpyrifos
- Cyclosarin
- Dichlorvos
- Dimethoate
- Metrifonate (irreversible)
- Sarin
- Soman
- Tabun
- VX
- VE
- VG
- VM
- Diazinon
- Malathion
- Parathion
|
- Carbamates
- Aldicarb
- Bendiocarb
- Bufencarb
- Carbaryl
- Carbendazim
- Carbetamide
- Carbofuran
- Carbosulfan
- Chlorbufam
- Chloropropham
- Ethiofencarb
- Formetanate
- Methiocarb
- Methomyl
- Oxamyl
- Phenmedipham
- Pinmicarb
- Pirimicarb
- Propamocarb
- Propham
- Propoxur
|
Natural Compounds[edit]
- Huperzine A
- Galantamine
- Onchidal
- Coumarins
- Celastrus paniculatus
Effects[edit]
Some major effects of cholinesterase inhibitors:
- Actions on the parasympathetic nervous system, (the parasympathetic branch of the autonomic nervous system) may cause bradycardia, hypotension, hypersecretion, bronchoconstriction, GI tract hypermotility, and decrease intraocular pressure.
- SLUDGE syndrome.
- Actions on the neuromuscular junction will result in prolonged muscle contraction.
Administration of reversible cholinoesterase inhibitors is contraindicated with those that have urinary retention due to obstruction.
Titration phase[edit]
When used in the central nervous system to alleviate neurological symptoms, such as rivastigmine in Alzheimer's disease, all cholinesterase inhibitors require doses to be increased gradually over several weeks, and this is usually referred to as the titration phase. Many other types drug treatments may require a titration or stepping up phase. This strategy is used to build tolerance to adverse events or to reach a desired clinical effect. [11]
See also[edit]
References[edit]
- ^ Pohanka, M (2012). "Acetylcholinesterase inhibitors; a patent review (2008–present)". Expert Opinion on Therapeutic Patents 22 (8): 871–886. doi:10.1517/13543776.2012.701620. PMID 22768972.
- ^ Colovic, MB; Krstic, Danijela Z.; Lazarevic-Pasti, Tamara D.; Bondzic, Aleksandra M.; Vasic, Vesna M. (2013). "Acetylcholinesterase Inhibitors: Pharmacology and Toxicology". Current Neuropharmacology 11 (3): 315–335. doi:10.2174/1570159X11311030006.
- ^ Consumer Reports; Drug Effectiveness Review Project (May 2012). "Evaluating Prescription Drugs Used to Treat: Alzheimer's Disease Comparing Effectiveness, Safety, and Price". Best Buy Drugs (Consumer Reports): 2. Retrieved 1 May 2013. , which claims Alzheimer’s Association guidance as a source
- ^ Inglis, F. (2002). "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia". International journal of clinical practice. Supplement (127): 45–63. PMID 12139367. edit
- ^ Eubanks LM, Rogers CJ, Beuscher AE, et al. (2006). "A molecular link between the active component of marijuana and Alzheimer's disease pathology". Mol. Pharm. 3 (6): 773–7. doi:10.1021/mp060066m. PMC 2562334. PMID 17140265.
- ^ Karadsheh, N; Kussie, P; Linthicum, DS (1991). "Inhibition of acetylcholinesterase by caffeine, anabasine, methyl pyrrolidine and their derivatives". Toxicology letters 55 (3): 335–42. doi:10.1016/0378-4274(91)90015-X. PMID 2003276.
- ^ Bauer, Brent A. Alzheimer's disease. mayoclinic.com
- ^ Wang, BS; Wang, H; Wei, ZH; Song, YY; Zhang, L; Chen, HZ (2009). "Efficacy and safety of natural acetylcholinesterase inhibitor huperzine A in the treatment of Alzheimer's disease: an updated meta-analysis". Journal of neural transmission (Vienna, Austria : 1996) 116 (4): 457–65. doi:10.1007/s00702-009-0189-x. PMID 19221692.
- ^ Rhee IK, I; Appels N, Hofte B, Karabatak B, Erkelens C, Stark LM, Flippin LA, Verpoorte R (November 2004). "Isolation of the Acetylcholinesterase Inhibitor Ungeremine from Nerine bowdenii by Preparative HPLC Coupled On-Line to a Flow Assay System". Biological & Pharmaceutical Bulletin 27 (11): 1804–1809. doi:10.1248/bpb.27.1804. PMID 15516727.
- ^ a b c d e f g h i j k l m n o p q r s t u v w x y Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. ISBN 0-443-07145-4. Page 156
- ^ Inglis, F (2002). "The tolerability and safety of cholinesterase inhibitors in the treatment of dementia". International journal of clinical practice. Supplement (127): 45–63. PMID 12139367.
External links[edit]
- Acetylcholinesterase inhibitors at the US National Library of Medicine Medical Subject Headings (MeSH)
Pharmacology: enzyme inhibition
|
|
Class |
- Competitive inhibition
- Uncompetitive inhibition
- Non-competitive inhibition
- Suicide inhibition
- Mixed inhibition
|
|
Substrate |
Oxidoreductase (EC 1) |
- 1.1 Aldose reductase
- HMG-CoA reductase
- 1.5 Dihydrofolate reductase
- 1.17 Xanthine oxidase
- Ribonucleotide reductase
|
|
Transferase (EC 2) |
- 2.1 COMT
- Thymidylate synthase
- 2.5 Dihydropteroate synthetase
- Farnesyltransferase
- 2.7 Nucleotidyltransferase
- Integrase
- Reverse transcriptase
- Protein kinase
|
|
Hydrolase (EC 3) |
- 3.1 Phosphodiesterase
- Acetylcholinesterase
- Ribonuclease
- 3.2 Polygalacturonase
- Neuraminidase
- Alpha-glucosidase
- 3.4 Protease: Exopeptidase
- Dipeptidyl peptidase-4
- ACE
- Endopeptidase
- Trypsin
- Renin
- Matrix metalloproteinase
- 3.5 Histone deacetylase
- Beta-lactamase
|
|
Lyase (EC 4) |
|
|
|
Psychoanaleptics: Antidementia agents (N06D)
|
|
Anticholinesterases |
- Cymserine
- Donepezil
- Galantamine
- Huperzine A (Huperzia serrata)
- Ladostigil
- Rivastigmine
- Tacrine
|
|
Others |
- Bifemelane
- Bilobalide (Ginkgo biloba)
- Cerlapirdine
- Ensaculin
- Latrepirdine
- Lecozotan
- Leteprinim
- Memantine
- Semagacestat
- Ergoloid
|
|
|
|
dsrd (o, p, m, p, a, d, s), sysi/epon, spvo
|
proc (eval/thrp), drug (N5A/5B/5C/6A/6B/6D)
|
|
|
|
Nootropics (N06B)
|
|
Acetylcholinesterases |
- Donepezil
- Galantamine
- Huperzine A (Huperzia Serrata)
- Ladostigil
- Rivastigmine
- Tacrine
|
|
Ampakines |
- CX-516
- CX-546
- CX-614
- CX-691
- CX-717
- IDRA-21
- LY-404,187
- LY-503,430
- PEPA
- Sunifiram
- Unifiram
|
|
D1 Agonists |
- 6-Br-APB
- A-77636
- Dihydrexidine
- Dinapsoline
- Doxanthrine
- SKF-81297
|
|
Eugeroics |
- Adrafinil
- Armodafinil
- Modafinil
|
|
GABAA α5 Inverse Agonists |
- α5IA
- L-655,708
- PWZ-029
- Ro4938581
- Suritozole
- TB-21007
- ZK-93426
|
|
H3 Antagonists |
- A-349,821
- ABT-239
- Ciproxifan
- GSK-189,254
|
|
mACh Agonists |
- Alvameline
- Arecoline
- Cevimeline
- CI-1017
- Milameline
- Sabcomeline
- Talsaclidine
- Tazomeline
- Xanomeline
|
|
nACh Agonists |
- AR-R17779
- Ispronicline
- Nicotine
- PNU-282,987
- SSR-180,711
- WAY-317,538
|
|
Racetams |
- Aniracetam
- Brivaracetam
- Coluracetam
- Etiracetam
- Fasoracetam
- Levetiracetam
- Nebracetam
- Nefiracetam
- Oxiracetam
- Phenylpiracetam
- Piracetam
- Pramiracetam
- Rolziracetam
- Seletracetam
|
|
Others |
- Acetylcarnitine
- Adafenoxate
- Bifemelane
- Bilobalide (Ginkgo Biloba)
- Carbenoxolone
- Cerlapirdine
- Choline (Lecithin)
- Citicoline
- Cyprodenate
- Dimethylethanolamine
- Ensaculin
- Fipexide
- Idebenone
- Indeloxazine
- ISRIB
- Latrepirdine
- Leteprinim
- Linopirdine
- Meclofenoxate
- Nicotinamide
- Nizofenone
- Pirisudanol
- Pyritinol
- S-17092
- Sulbutiamine
- Taltirelin
- Teniloxazine
- Tricyanoaminopropene
- Vinpocetine
|
|
Cholinergics
|
|
Receptor ligands
|
|
mAChR
|
- Agonists: 77-LH-28-1
- AC-42
- AC-260,584
- Aceclidine
- Acetylcholine
- AF30
- AF150(S)
- AF267B
- AFDX-384
- Alvameline
- AQRA-741
- Arecoline
- Bethanechol
- Butyrylcholine
- Carbachol
- CDD-0034
- CDD-0078
- CDD-0097
- CDD-0098
- CDD-0102
- Cevimeline
- Choline
- cis-Dioxolane
- Ethoxysebacylcholine
- LY-593,039
- L-689,660
- LY-2,033,298
- McNA343
- Methacholine
- Milameline
- Muscarine
- NGX-267
- Ocvimeline
- Oxotremorine
- PD-151,832
- Pilocarpine
- RS86
- Sabcomeline
- SDZ 210-086
- Sebacylcholine
- Suberylcholine
- Talsaclidine
- Tazomeline
- Thiopilocarpine
- Vedaclidine
- VU-0029767
- VU-0090157
- VU-0152099
- VU-0152100
- VU-0238429
- WAY-132,983
- Xanomeline
- YM-796
Antagonists: 3-Quinuclidinyl Benzilate
- 4-DAMP
- Aclidinium Bromide
- Anisodamine
- Anisodine
- Atropine
- Atropine Methonitrate
- Benactyzine
- Benzatropine/Benztropine
- Benzydamine
- BIBN 99
- Biperiden
- Bornaprine
- CAR-226,086
- CAR-301,060
- CAR-302,196
- CAR-302,282
- CAR-302,368
- CAR-302,537
- CAR-302,668
- CS-27349
- Cyclobenzaprine
- Cyclopentolate
- Darifenacin
- DAU-5884
- Dimethindene
- Dexetimide
- DIBD
- Dicyclomine/Dicycloverine
- Ditran
- EA-3167
- EA-3443
- EA-3580
- EA-3834
- Etanautine
- Etybenzatropine/Ethylbenztropine
- Flavoxate
- Himbacine
- HL-031,120
- Ipratropium bromide
- J-104,129
- Hyoscyamine
- Mamba Toxin 3
- Mamba Toxin 7
- Mazaticol
- Mebeverine
- Methoctramine
- Metixene
- N-Ethyl-3-Piperidyl Benzilate
- N-Methyl-3-Piperidyl Benzilate
- Orphenadrine
- Otenzepad
- Oxybutynin
- PBID
- PD-102,807
- PD-0298029
- Phenglutarimide
- Phenyltoloxamine
- Pirenzepine
- Piroheptine
- Procyclidine
- Profenamine
- RU-47,213
- SCH-57,790
- SCH-72,788
- SCH-217,443
- Scopolamine/Hyoscine
- Solifenacin
- Telenzepine
- Tiotropium bromide
- Tolterodine
- Trihexyphenidyl
- Tripitamine
- Tropatepine
- Tropicamide
- WIN-2299
- Xanomeline
- Zamifenacin; Others: 1st Generation Antihistamines (Brompheniramine
- chlorphenamine
- cyproheptadine
- dimenhydrinate
- diphenhydramine
- doxylamine
- mepyramine/pyrilamine
- phenindamine
- pheniramine
- tripelennamine
- triprolidine, etc)
- Tricyclic Antidepressants (Amitriptyline
- doxepin
- trimipramine, etc)
- Tetracyclic Antidepressants (Amoxapine
- maprotiline, etc)
- Typical Antipsychotics (Chlorpromazine
- thioridazine, etc)
- Atypical Antipsychotics (Clozapine
- olanzapine, etc.)
|
|
nAChR
|
- Agonists: 5-HIAA
- A-84,543
- A-366,833
- A-582,941
- A-867,744
- ABT-202
- ABT-418
- ABT-560
- ABT-894
- Acetylcholine
- Altinicline
- Anabasine
- Anatoxin-a
- AR-R17779
- Butinoline
- Butyrylcholine
- Carbachol
- Choline
- Cotinine
- Cytisine
- Decamethonium
- Desformylflustrabromine
- Dianicline
- Dimethylphenylpiperazinium
- Epibatidine
- Epiboxidine
- Ethanol
- Ethoxysebacylcholine
- EVP-4473
- EVP-6124
- Galantamine
- GTS-21
- Ispronicline
- Lobeline
- MEM-63,908/RG-3487
- Nicotine
- NS-1738
- PHA-543,613
- PHA-709,829
- PNU-120,596
- PNU-282,987
- Pozanicline
- Rivanicline
- RJR-2429
- Sazetidine A
- Sebacylcholine
- SIB-1508Y
- SIB-1553A
- SSR-180,711
- Suberylcholine
- Suxamethonium/Succinylcholine
- TC-1698
- TC-1734
- TC-1827
- TC-2216
- TC-5214
- TC-5619
- TC-6683
- Tebanicline
- Tropisetron
- UB-165
- Varenicline
- WAY-317,538
- XY-4083
Antagonists: 18-Methoxycoronaridine
- α-Bungarotoxin
- α-Conotoxin
- Alcuronium
- Amantadine
- Anatruxonium
- Atracurium
- Bupropion
- Chandonium
- Chlorisondamine
- Cisatracurium
- Coclaurine
- Coronaridine
- Dacuronium
- Decamethonium
- Dextromethorphan
- Dextropropoxyphene
- Dextrorphan
- Diadonium
- DHβE
- Dimethyltubocurarine/Metocurine
- Dipyrandium
- Dizocilpine/MK-801
- Doxacurium
- Duador
- Esketamine
- Fazadinium
- Gallamine
- Hexafluronium
- Hexamethonium/Benzohexonium
- Ibogaine
- Isoflurane
- Ketamine
- Kynurenic acid
- Laudexium/Laudolissin
- Levacetylmethadol
- Malouetine
- Mecamylamine
- Memantine
- Methadone (Levomethadone)
- Methorphan/Racemethorphan
- Methyllycaconitine
- Metocurine
- Mivacurium
- Morphanol/Racemorphan
- Neramexane
- Nitrous Oxide
- Pancuronium
- Pempidine
- Pentamine
- Pentolinium
- Phencyclidine
- Pipecuronium
- Radafaxine
- Rapacuronium
- Rocuronium
- Surugatoxin
- Thiocolchicoside
- Toxiferine
- Trimethaphan
- Tropeinium
- Tubocurarine
- Vecuronium
- Xenon
|
|
|
|
Reuptake inhibitors
|
|
Plasmalemmal
|
CHT Inhibitors
|
- Hemicholinium-3/Hemicholine
- Triethylcholine
|
|
|
Vesicular
|
|
|
|
|
Enzyme inhibitors
|
|
Anabolism
|
ChAT inhibitors
|
- 1-(-Benzoylethyl)pyridinium
- 2-(α-Naphthoyl)ethyltrimethylammonium
- 3-Chloro-4-stillbazole
- 4-(1-Naphthylvinyl)pyridine
- Acetylseco hemicholinium-3
- Acryloylcholine
- AF64A
- B115
- BETA
- CM-54,903
- N,N-Dimethylaminoethylacrylate
- N,N-Dimethylaminoethylchloroacetate
|
|
|
Catabolism
|
AChE inhibitors
|
|
|
BChE inhibitors
|
- Cymserine * Many of the acetylcholinesterase inhibitors listed above act as butyrylcholinesterase inhibitors.
|
|
|
|
|
Others
|
|
Precursors
|
- Choline (Lecithin)
- Citicoline
- Cyprodenate
- Dimethylethanolamine
- Glycerophosphocholine
- Meclofenoxate/Centrophenoxine
- Phosphatidylcholine
- Phosphatidylethanolamine
- Phosphorylcholine
- Pirisudanol
|
|
Cofactors
|
- Acetic acid
- Acetylcarnitine
- Acetyl-coA
- Vitamin B5 (Pantethine
- Pantetheine
- Panthenol)
|
|
Others
|
- Acetylcholine releasing agents: α-Latrotoxin
- β-Bungarotoxin; Acetylcholine release inhibitors: Botulinum toxin (Botox); Acetylcholinesterase reactivators: Asoxime
- Obidoxime
- Pralidoxime
|
|
|
|
UpToDate Contents
全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.
English Journal
- Pharmacological treatments for neuropsychiatric symptoms of dementia in long-term care: a systematic review.
- Seitz DP, Gill SS, Herrmann N, Brisbin S, Rapoport MJ, Rines J, Wilson K, Le Clair K, Conn DK.SourceDepartment of Psychiatry, Queen's University, Kingston, Ontario, Canada.
- International psychogeriatrics / IPA.Int Psychogeriatr.2013 Feb;25(2):185-203. doi: 10.1017/S1041610212001627. Epub 2012 Oct 19.
- ABSTRACT Background: Medications are frequently prescribed for neuropsychiatric symptoms (NPS) associated with dementia, although information on the efficacy and safety of medications for NPS specifically in long-term care (LTC) settings is limited. The objective of this st
- PMID 23083438
- Kinetic and physicochemical properties of brain acetylcholinesterase from the peacock bass (Cichla ocellaris) and in vitro effect of pesticides and metal ions.
- Silva KC, Assis CR, Oliveira VM, Carvalho LB Jr, Bezerra RS.SourceDepartamento de Bioquímica and Laboratório de Imunopatologia Keizo Asami, Universidade Federal de Pernambuco, Recife-PE, Brazil.
- Aquatic toxicology (Amsterdam, Netherlands).Aquat Toxicol.2013 Jan 15;126:191-7. doi: 10.1016/j.aquatox.2012.11.001. Epub 2012 Nov 9.
- Brain acetylcholinesterase (AChE; EC 3.1.1.7) from peacock bass (Cichla ocellaris) was characterized and the effect of organophosphorus and carbamate pesticides as well as ions and heavy metals was evaluated. The kinetic parameters K(m) and V(max) were determined as 0.769mM and 0.189U/mg of protein
- PMID 23220411
- Synthesis, molecular modeling and evaluation of novel N'-2-(4-benzylpiperidin-/piperazin-1-yl)acylhydrazone derivatives as dual inhibitors for cholinesterases and Aβ aggregation.
- Ozturan Özer E, Unsal Tan O, Ozadali K, Küçükkılınç T, Balkan A, Uçar G.SourceDepartment of Biochemistry, Faculty of Medicine, Başkent University, Ankara 06530, Turkey.
- Bioorganic & medicinal chemistry letters.Bioorg Med Chem Lett.2013 Jan 15;23(2):440-3. doi: 10.1016/j.bmcl.2012.11.064. Epub 2012 Nov 28.
- To develop new drugs for treatment of Alzheimer's disease, a group of N'-2-(4-Benzylpiperidin-/piperazin-1-yl)acylhydrazones was designed, synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase and aggregation of amyloid beta peptides (1-40, 1-42 and 1-40_1-4
- PMID 23273219
Japanese Journal
- 仰臥位高血圧・立位低血圧を伴う糖尿病性腎症血液透析患者の血圧コントロール
- 田中 勝喜,西口 健介,高折 光司,村上 徹,岸本 聡子,玉置 佐奈美,井ノ口 眞澄美,左海 佳奈子,門脇 勧,織田 浩彰,御厨 亮子,桑原 隆
- 日本透析医学会雑誌 = Journal of Japanese Society for Dialysis Therapy 44(5), 449-453, 2011-05-28
- 67歳,女性.糖尿病性腎症による血液透析歴16年.週3回3.5時間の維持透析で,体重増加は基本体重(40.2 kg)の約4%である.起床時の血圧は190/90 mmHg,透析前座位血圧120/60 mmHg,透析開始直後(仰臥位)血圧200/90 mmHgにも上昇する.透析終了後起立により血圧が90/50 mmHgまで低下し,当日はほとんど起立できない状況が続いていた.透析中の仰臥位血圧上昇につい …
- NAID 10029406867
★リンクテーブル★
[★]
- 英
- cholinesterase inhibitor cholinesterase inhibitors
- 同
- 抗コリンエステラーゼ薬 anticholinesterase
- 関
- アセチルコリン、アセチルコリン受容体、副交感神経
コリンエステラーゼ阻害薬=
- アルツハイマー病の治療薬
作用機序
活性部位に結合
- エドロフォニウムは四級アミンなので腎臓より速やかに排泄され、持続時間が短い。
酵素ををカルバモイル化
- フィゾスチグミンやネオスチグミンは活性化部位に位置するセリン残基のヒドロキシ基にカルバモイル基(NH2CO-)を転移することで、機能を可逆的に失わせる (GOO.204)
酵素をリン酸化
薬理作用
動態
適応
臨床応用
注意
禁忌
副作用
[★]
- 関
- acetylcholinesterase inhibitor、anticholinesterase、cholinesterase inhibitor
[★]
- 英
- cholinesterase inhibitor
- 関
- 抗コリンエステラーゼ薬、アセチルコリンエステラーゼ阻害薬、コリンエステラーゼ阻害薬
[★]
アセチルコリンエステラーゼ阻害薬
[★]
アセチルコリンエステラーゼ阻害薬
[★]
コリンエステラーゼ阻害薬
[★]
- 関
- abrogate、block、depress、depression、deter、inhibition、interdict、prevent、prevention、repress、repression、restrain、restraint、suppress、suppression
[★]
- 関
- blocker、depressant、suppressant
[★]
コリンエステラーゼ
[★]
コリンエステラーゼ